Recent advances in post autologous transplantation maintenance therapies in B-cell non-Hodgkin lymphomas.

ABSTRACT: Lymphomas constitute the second most common indication for high dose therapy (HDT) followed by autologous hematopoietic cell transplantation (auto-HCT). The intent of administering HDT in these heterogeneous disorders varies from cure (e.g., in relapsed aggressive lymphomas) to disease control (e.g., most indolent lymphomas). Regardless of the underlying histology or remission status at transplantation, disease relapse remains the number one cause of post auto-HCT therapy failure and mortality. The last decade has seen a proliferation of clinical studies looking at prevention of post auto-HCT therapy failure with various maintenance strategies. The benefit of such therapies is in turn dependent on disease histology and timing of transplantation. In relapsed, chemosensitive diffuse large B-

SUBMITTER: Epperla N 

PROVIDER: S-EPMC4580930 | biostudies-literature | 2015 Sep

REPOSITORIES: biostudies-literature